Results 41 to 50 of about 220,602 (307)

Subjective performance assessment protocol for visual explanations-based face verification explainability

EURASIP Journal on Image and Video Processing
The integration of Face Verification (FV) systems into multiple critical moments of daily life has become increasingly prevalent, raising concerns regarding the transparency and reliability of these systems.
Naima Bousnina, João Ascenso, Paulo Lobato Correia, Fernando Pereira   +3 more
doaj   +1 more source

Situativität, Funktionalität und Vertrauen: Ergebnisse einer szenariobasierten Interviewstudie zur Erklärbarkeit von KI in der Medizin

TATuP – Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis
A central requirement for the use of artificial intelligence (AI) in medicine is its explainability, i. e., the provision of addressee-oriented information about its functioning.
Manuela Marquardt, Philipp Graf, Eva Jansen, Stefan Hillmann, Jan-Niklas Voigt-Antons   +4 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Implementing Health‐Related Quality of Life Assessment in Pediatric Oncology: A Feasibility Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background There is growing interest in embedding health‐related quality of life (HRQoL) assessment and patient‐reported outcome measures (PROMs) within clinical cancer care. This study evaluated the feasibility, acceptability, and usability of implementing an electronic PROM (ePROM) platform to measure HRQoL in children with cancer ...
Mikaela Doig, Sophie Jessop, Jordan R. Hansford, Hien Le, Matthew O'Connor, Peter Gorayski, Andrew Cunningham, Amanda Hutchinson, Victoria Bedford, Eva Bezak, Nayana Parange, Kelly Skelton, Timothy Price, Michala Short   +13 more
wiley   +1 more source

Parent Quality of Life at Two Years Following Their Child's Completion of Acute Lymphoblastic Leukemia Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Parents of children treated for acute lymphoblastic leukemia (ALL) often experience significant caregiver burden and disruption to their well‐being. While parent quality of life (QoL) during treatment is well characterized, little is known about outcomes during early survivorship.
Sara Dal Pra, Maria McCarthy, Michael Takagi, Cinzia De Luca   +3 more
wiley   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Incidence and Risk Factors of Serious Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia: A CYP‐C Population‐Based Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteonecrosis (ON) is a debilitating complication of acute lymphoblastic leukemia (ALL) therapy. While numerous studies have explored its incidence and associated risk factors, investigations using large‐scale cohorts remain important to characterize ON across heterogeneous populations.
Noémie de Villiers, Chantal Éthier, Caroline Laverdière, Nathalie Alos, Thai Hoa Tran, Marie‐Claude Pelland‐Marcotte   +5 more
wiley   +1 more source

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods A multicenter retrospective review was performed
Hannah N. Rinehardt, Elisabeth T. Tracy, Anghela Paredes, Catherine Beckhorn, Harold J. Leraas, Joseph Fusco, Katlyn G. McKay, Nelly‐Ange T. Kontchou, Zachary J. Kastenberg, David W. Hoyt, Jonathan Roach, Emily K. Myers, Nicholas G. Cost, Bhargava Mullapudi, Charles R. Marchese, Amanda R. Jensen, Timothy B. Lautz, Michela Carter, Roshni Dasgupta, John Lundstedt, Joseph G. Brungardt, Lindsay Talbot, Andrew M. Davidoff, Andrew J. Murphy, Jennifer H. Aldrink, Sara Mansfield, Nelson Piche, Annie Le‐Nguyen, Dave R. Lal, Brian T. Craig, Jennifer M. Schuh, Barrett P. Cromeens, Sindhu Mannava, Shannon Castle, Adriana Lopez, Kelsey Mello, Joshua Short, Robin T. Petroze, Shay Rajaval, Grace R. Thompson, Peter Mattei, David H. Rothstein, Elizabeth Fialkowski, Kathryn Fowler, Nathan Martchenke, Barrie S. Rich, Richard D. Glick, Erin G. Brown, Kathleen Doyle, Paige Abril, Natashia Seemann, Jacob Davidson, Claire A. Wilson, Hau D. Le, Devashish Joshi, Michael Stellon, Tamer Ahmed, Alexandra Dimmer, Peter F. Ehrlich, Maya Hammoud, Keyonna Williams, Christa N. Grant, Merit Gorgy, Stephanie F. Polites, Julia Debertin, Danielle B. Cameron, Alyssa Stetson, Eugene S. Kim, William G. Lee, Aaron Barkhordar, Mary Austin, Brian A. Coakley, Anastasia Kahan, Joseph T. Murphy, Michael Pitonak, Chloé Boehmer, Marcus M. Malek   +76 more
wiley   +1 more source

Explainable AI as evidence of fair decisions

Frontiers in Psychology, 2023
This paper will propose that explanations are valuable to those impacted by a model's decisions (model patients) to the extent that they provide evidence that a past adverse decision was unfair.
Derek Leben
doaj   +1 more source